Blinded,Randomized,Multicenter phase III Study to evaluate single administration PEG-rhG-CSF100ug/kg or 6mg fixed-dose once per cycle versus daily rhG-CSFas an adjunct to chemotherapy in patients with breast cancer or NSCLC

Trial Profile

Blinded,Randomized,Multicenter phase III Study to evaluate single administration PEG-rhG-CSF100ug/kg or 6mg fixed-dose once per cycle versus daily rhG-CSFas an adjunct to chemotherapy in patients with breast cancer or NSCLC

Completed
Phase of Trial: Phase III

Latest Information Update: 06 May 2016

At a glance

  • Drugs Pegfilgrastim (Primary) ; Filgrastim
  • Indications Neutropenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 May 2016 According to a Qilu Pharma media release, the CFDA approved PEG Recombinant Human Granulocyte Colony Stimulating Factor (PEG-rh-G-CSF) injection on 26-Aug-2015.
    • 28 Apr 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top